• 1

    JemalASiegelRXuJWardE. Cancer statistics, 2010. CA Cancer J Clin2010;60:277300.

  • 2

    HoppeRTMauchPTArmitageJO. Hodgkin Lymphoma2nd ed.Philadelphia, PA: Lippincott Williams and Wilkins; 2007.

  • 3

    SwerdlowSHCampoEHarrisNL. eds. WHO classification of tumours of haematopoietic and lymphoid tissues4th ed.Lyon, France: IARC; 2008.

  • 4

    CarbonePPKaplanHSMusshoffK. Report of the committee on hodgkin’s disease staging classification. Cancer Res1971;31:18601861.

  • 5

    MauchPGoodmanRHellmanS. The significance of mediastinal involvement in early stage Hodgkin’s disease. Cancer1978;42:10391045.

  • 6

    ListerTACrowtherDSutcliffeSB. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol1989;7:16301636.

    • Search Google Scholar
    • Export Citation
  • 7

    Henry-AmarMFriedmanSHayatM. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med1991;114:361365.

    • Search Google Scholar
    • Export Citation
  • 8

    TubianaMHenry-AmarMHayatM. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer1984;54:885894.

    • Search Google Scholar
    • Export Citation
  • 9

    HasencleverDDiehlV. A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med1998;339:15061514.

    • Search Google Scholar
    • Export Citation
  • 10

    ChesonBDHorningSJCoiffierB. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol1999;17:1244.

    • Search Google Scholar
    • Export Citation
  • 11

    ChesonBDPfistnerBJuweidME. Revised response criteria for malignant lymphoma. J Clin Oncol2007;25:579586.

  • 12

    CarawayNP. Strategies to diagnose lymphoproliferative disorders by fine-needle aspiration by using ancillary studies. Cancer2005;105:432442.

    • Search Google Scholar
    • Export Citation
  • 13

    HehnSTGroganTMMillerTP. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol2004;22:30463052.

  • 14

    MedaBABussDHWoodruffRD. Diagnosis and subclassification of primary and recurrent lymphoma. The usefulness and limitations of combined fine-needle aspiration cytomorphology and flow cytometry. Am J Clin Pathol2000;113:688699.

    • Search Google Scholar
    • Export Citation
  • 15

    SieniawskiMReinekeTNogovaL. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Blood2008;111:7176.

    • Search Google Scholar
    • Export Citation
  • 16

    van der KaaijMAvan Echten-ArendsJSimonsAHKluin-NelemansHC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol2010;28:168179.

    • Search Google Scholar
    • Export Citation
  • 17

    SeamPJuweidMEChesonBD. The role of FDG-PET scans in patients with lymphoma. Blood2007;110:35073516.

  • 18

    IsasiCRLuPBlaufoxMD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer2005;104:10661074.

    • Search Google Scholar
    • Export Citation
  • 19

    JuweidME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology2006;2006:259265.

    • Search Google Scholar
    • Export Citation
  • 20

    de WitMBohuslavizkiKHBuchertR. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma. Ann Oncol2001;12:2937.

    • Search Google Scholar
    • Export Citation
  • 21

    GuayCLepineMVerreaultJBenardF. Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med2003;44:12251231.

    • Search Google Scholar
    • Export Citation
  • 22

    GallaminiARigacciLMerliF. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica2006;91:475481.

    • Search Google Scholar
    • Export Citation
  • 23

    GallaminiAHutchingsMAvigdorAPolliackA. Early interim PET scan in Hodgkin lymphoma: where do we stand?Leuk Lymphoma2008;49:659662.

  • 24

    TerasawaTLauJBardetS. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol2009;27:19061914.

    • Search Google Scholar
    • Export Citation
  • 25

    GallaminiAHutchingsMRigacciL. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol2007;25:37463752.

    • Search Google Scholar
    • Export Citation
  • 26

    HutchingsMLoftAHansenM. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood2006;107:5259.

    • Search Google Scholar
    • Export Citation
  • 27

    AdvaniRMaedaLLavoriP. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol2007;25:39023907.

    • Search Google Scholar
    • Export Citation
  • 28

    MarkovaJKobeCSkopalovaM. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin’s lymphoma has a high negative predictive value. Ann Oncol2009;20:12701274.

    • Search Google Scholar
    • Export Citation
  • 29

    DannEJBar-ShalomRTamirA. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood2007;109:905909.

    • Search Google Scholar
    • Export Citation
  • 30

    SherDJMauchPMVan Den AbbeeleA. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin’s lymphoma: the importance of involved-field radiotherapy. Ann Oncol2009;20:18481853.

    • Search Google Scholar
    • Export Citation
  • 31

    PodoloffDAAdvaniRHAllredC. NCCN Task Force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw2007;5(Suppl 1):S122; quiz S23–22.

    • Search Google Scholar
    • Export Citation
  • 32

    DuhmkeEFranklinJPfreundschuhM. Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol2001;19:29052914.

    • Search Google Scholar
    • Export Citation
  • 33

    GustavssonAOstermanBCavallin-StahlE. A systematic overview of radiation therapy effects in Hodgkin’s lymphoma. Acta Oncol2003;42:589604.

    • Search Google Scholar
    • Export Citation
  • 34

    ConnorsJM. State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol2005;23:64006408.

  • 35

    MacdonaldDAConnorsJM. New strategies for the treatment of early stages of Hodgkin’s lymphoma. Hematol Oncol Clin North Am2007;21:871880.

    • Search Google Scholar
    • Export Citation
  • 36

    SantoroABonadonnaGValagussaP. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol1987;5:2737.

    • Search Google Scholar
    • Export Citation
  • 37

    HorningSJHoppeRTBreslinS. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol2002;20:630637.

    • Search Google Scholar
    • Export Citation
  • 38

    AdvaniRHHoppeRTBaerDM. Efficacy of abbreviated Stanford V chemotherapy and involved field radiotherapy in early stage Hodgkin’s disease: mature results of the G4 trial [abstract]. Blood2009;114:Abstract 1670.

    • Search Google Scholar
    • Export Citation
  • 39

    AbuzetunJYLoberizaFVoseJ. The Stanford V regimen is effective in patients with good risk Hodgkin lymphoma but radiotherapy is a necessary component. Br J Haematol2009;144:531537.

    • Search Google Scholar
    • Export Citation
  • 40

    BonadonnaGBonfanteVVivianiS. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol2004;22:28352841.

    • Search Google Scholar
    • Export Citation
  • 41

    EngertASchillerPJostingA. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol2003;21:36013608.

    • Search Google Scholar
    • Export Citation
  • 42

    EngertAPlutschowAEichHT. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med2010;363:640652.

    • Search Google Scholar
    • Export Citation
  • 43

    HorningSJHoppeRTAdvaniR. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin’s disease: mature data in early and advanced stage patients [asbtract]. Blood2004;104:Abstract 308.

    • Search Google Scholar
    • Export Citation
  • 44

    GobbiPGLevisAChisesiT. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol2005;23:91989207.

    • Search Google Scholar
    • Export Citation
  • 45

    AversaSMSalvagnoLSoraruM. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin’s disease. Acta Haematol2004;112:141147.

    • Search Google Scholar
    • Export Citation
  • 46

    Edwards-BennettSMJacksLMMoskowitzCH. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol2010;21:574581.

    • Search Google Scholar
    • Export Citation
  • 47

    HoskinPJLowryLHorwichA. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol2009;27:53905396.

    • Search Google Scholar
    • Export Citation
  • 48

    GordonLIHongFFisherRI. A randomized phase III trial of ABVD vs. Stanford V +/radiation therapy in locally extensive and advanced stage Hodgkin’s lymphoma: an Intergroup study coordinated by the Eastern Cooperatve Oncology Group (E2496) [abstract]. Blood2010;116:Abstract 415.

    • Search Google Scholar
    • Export Citation
  • 49

    AdvaniRHongFFisherRI. Randomized phase III trial comparing ABVD + radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: a subset analysis of the US Intergroup Trial E2496. Blood2010;116:Abstract 416.

    • Search Google Scholar
    • Export Citation
  • 50

    EichHTDiehlVGörgenH. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol2010;28:41994206.

    • Search Google Scholar
    • Export Citation
  • 51

    LongoDGlatsteinEDuffeyP. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol1991;9:906917.

    • Search Google Scholar
    • Export Citation
  • 52

    MeyerRMGospodarowiczMKConnorsJM. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol2005;23:46344642.

    • Search Google Scholar
    • Export Citation
  • 53

    Rueda DominguezAMarquezAGumaJ. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol2004;15:17981804.

    • Search Google Scholar
    • Export Citation
  • 54

    StrausDJPortlockCSQinJ. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood2004;104:34833489.

    • Search Google Scholar
    • Export Citation
  • 55

    CanellosGPAbramsonJSFisherDCLaCasceAS. Treatment of favorable, limited-stage Hodgkin’s lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol2010;28:16111615.

    • Search Google Scholar
    • Export Citation
  • 56

    BeharRAHorningSJHoppeRT. Hodgkin’s disease with bulky mediastinal involvement: effective management with combined modality therapy. Int J Radiat Oncol Biol Phys1993;25:771776.

    • Search Google Scholar
    • Export Citation
  • 57

    LongoDLRussoADuffeyPL. Treatment of advanced-stage massive mediastinal Hodgkin’s disease: the case for combined modality treatment. J Clin Oncol1991;9:227235.

    • Search Google Scholar
    • Export Citation
  • 58

    DeVitaVTJrSimonRMHubbardSM. Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med1980;92:587595.

    • Search Google Scholar
    • Export Citation
  • 59

    CanellosGPAndersonJRPropertKJ. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med1992;327:14781484.

    • Search Google Scholar
    • Export Citation
  • 60

    DugganDBPetroniGRJohnsonJL. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol2003;21:607614.

    • Search Google Scholar
    • Export Citation
  • 61

    JohnsonPWRadfordJACullenMH. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin’s lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol2005;23:92089218.

    • Search Google Scholar
    • Export Citation
  • 62

    JohnsonPWSydesMRHancockBW. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol2010:33523359.

    • Search Google Scholar
    • Export Citation
  • 63

    DiehlVSieberMRufferU. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. The German Hodgkin’s Lymphoma Study Group. Ann Oncol1997;8:143148.

    • Search Google Scholar
    • Export Citation
  • 64

    DiehlVFranklinJPfreundschuhM. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med2003;348:23862395.

    • Search Google Scholar
    • Export Citation
  • 65

    EngertADiehlVFranklinJ. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol2009;27:45484554.

    • Search Google Scholar
    • Export Citation
  • 66

    FedericoMLuminariSIannittoE. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol2009;27:805811.

    • Search Google Scholar
    • Export Citation
  • 67

    CarellaAMBelleiMBriceP. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica2009;94:146148.

    • Search Google Scholar
    • Export Citation
  • 68

    ProctorSJMackieMDawsonA. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin’s disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer2002;38:795806.

    • Search Google Scholar
    • Export Citation
  • 69

    AlemanBMRaemaekersJMTomisicR. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys2007;67:1930.

    • Search Google Scholar
    • Export Citation
  • 70

    AlemanBMRaemaekersJMTirelliU. Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med2003;348:23962406.

  • 71

    FabianCJMansfieldCMDahlbergS. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med1994;120:903912.

    • Search Google Scholar
    • Export Citation
  • 72

    LaskarSGuptaTVimalS. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?J Clin Oncol2004;22:6268.

    • Search Google Scholar
    • Export Citation
  • 73

    KobeCDietleinMFranklinJ. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood2008;112:39893994.

    • Search Google Scholar
    • Export Citation
  • 74

    EngertAKobeCMarkovaJ. Assessment of residual bulky tumor using FDG-PET in patients with advanced-stage Hodgkin lymphoma after completion of chemotherapy: final report of the GHSG HD15 trial [abstract]. Blood2010;116:Abstract 764.

    • Search Google Scholar
    • Export Citation
  • 75

    LeeAILaCasceAS. Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist2009;14:739751.

  • 76

    NogovaLReinekeTBrillantC. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol2008;26:434439.

    • Search Google Scholar
    • Export Citation
  • 77

    DiehlVSextroMFranklinJ. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol1999;17:776783.

    • Search Google Scholar
    • Export Citation
  • 78

    NogovaLReinekeTEichHT. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol2005;16:16831687.

    • Search Google Scholar
    • Export Citation
  • 79

    SchlembachPJWilderRBJonesD. Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J2002;8:377383.

  • 80

    TsaiHKMauchPM. Nodular lymphocyte-predominant hodgkin lymphoma. Semin Radiat Oncol2007;17:184189.

  • 81

    WilderRBSchlembachPJJonesD. European Organization for Research and Treatment of Cancer and Groupe d’Etude des Lymphomes de l’Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer2002;94:17311738.

    • Search Google Scholar
    • Export Citation
  • 82

    WirthAYuenKBartonM. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer2005;104:12211229.

    • Search Google Scholar
    • Export Citation
  • 83

    ChenRCChinMSNgAK. Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol2010;28:136141.

    • Search Google Scholar
    • Export Citation
  • 84

    FeugierPLabouyrieEDjeridaneM. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood2004;104:26752681.

    • Search Google Scholar
    • Export Citation
  • 85

    JacksonCSirohiBCunninghamD. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. Ann Oncol2010;21:20612068.

    • Search Google Scholar
    • Export Citation
  • 86

    MaedaLSAdvaniRH. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol2009;21:397400.

    • Search Google Scholar
    • Export Citation
  • 87

    EkstrandBCLucasJBHorwitzSM. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood2003;101:42854289.

    • Search Google Scholar
    • Export Citation
  • 88

    HorningSJBartlettNLBreslinS. Results of a prospective phase II Trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin’s disease (NLPHD) [abstract]. Blood2007;110:Abstract 644.

    • Search Google Scholar
    • Export Citation
  • 89

    SchulzHRehwaldUMorschhauserF. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood2008;111:109111.

    • Search Google Scholar
    • Export Citation
  • 90

    AzimHAJrPruneriGCocorocchioE. Rituximab in lymphocyte-predominant Hodgkin disease. Oncology2009;76:2629.

  • 91

    SavageKJSkinniderBAl MansourM. Incorporation of ABVD increases cure rates of patients with limited stage nodular lymphocyte predominant Hodgkin Lymphoma (NLPHL) [abstract]. Blood2010;116:Abstract 3887.

    • Search Google Scholar
    • Export Citation
  • 92

    CanellosGPMauchP. What is the appropriate systemic chemotherapy for lymphocyte-predominant Hodgkin’s Lymphoma?J Clin Oncol2010;28:e8.

    • Search Google Scholar
    • Export Citation
  • 93

    UnalASariIDenizK. Familial nodular lymphocyte predominant Hodgkin lymphoma: successful treatment with CHOP plus rituximabLeuk Lymphoma2005;46:16131617.

    • Search Google Scholar
    • Export Citation
  • 94

    ShankarAGDawSHallG. Treatment of children & adolescents with early stage nodular lymphocyte predominant Hodgkin Lymphoma with a low intensity short duration chemotherapy regimen [CVP]—on behalf of the EuroNet-PHL group [abstract]. Blood2006;108:Abstract 2471.

    • Search Google Scholar
    • Export Citation
  • 95

    MiettinenMFranssilaKOSaxenE. Hodgkin’s disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin’s lymphomas. Cancer1983;51:22932300.

    • Search Google Scholar
    • Export Citation
  • 96

    HuangJZWeisenburgerDDVoseJM. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma2004;45:15511557.

    • Search Google Scholar
    • Export Citation
  • 97

    Al-MansourMConnorsJMGascoyneRD. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin’s lymphoma. J Clin Oncol2010;28:793799.

    • Search Google Scholar
    • Export Citation
  • 98

    MauchPNgAAlemanB. Report from the Rockefellar Foundation sponsored international workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin’s disease. Eur J Haematol Suppl2005:6876.

    • Search Google Scholar
    • Export Citation
  • 99

    FranklinJPluetschowAPausM. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol2006;17:17491760.

    • Search Google Scholar
    • Export Citation
  • 100

    MudieNYSwerdlowAJHigginsCD. Risk of second malignancy after non-Hodgkin’s lymphoma: a British cohort study. J Clin Oncol2006;24:15681574.

    • Search Google Scholar
    • Export Citation
  • 101

    AdamsMJLipsitzSRColanSD. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol2004;22:31393148.

    • Search Google Scholar
    • Export Citation
  • 102

    AlemanBMvan den Belt-DuseboutAWDe BruinML. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood2007;109:18781886.

  • 103

    HeidenreichPAHancockSLLeeBK. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol2003;42:743749.

  • 104

    MartinWGRistowKMHabermannTM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol2005;23:76147620.

    • Search Google Scholar
    • Export Citation
  • 105

    BoletiEMeadGM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol2007;18:376380.

    • Search Google Scholar
    • Export Citation
  • 106

    EvensAMCilleyJOrtizT. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol2007;137:545552.

    • Search Google Scholar
    • Export Citation
  • 107

    LinchDCWinfieldDGoldstoneAH. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet1993;341:10511054.

    • Search Google Scholar
    • Export Citation
  • 108

    SchmitzNPfistnerBSextroM. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet2002;359:20652071.

    • Search Google Scholar
    • Export Citation
  • 109

    BricePBouabdallahRMoreauP. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant1997;20:2126.

    • Search Google Scholar
    • Export Citation
  • 110

    MoskowitzCHNimerSDZelenetzAD. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood2001;97:616623.

    • Search Google Scholar
    • Export Citation
  • 111

    MoskowitzCHYahalomJZelenetzAD. High-dose chemoradiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol2010;148:890897.

    • Search Google Scholar
    • Export Citation
  • 112

    JostingAFranklinJMayM. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol2002;20:221230.

    • Search Google Scholar
    • Export Citation
  • 113

    SuredaAConstansMIriondoA. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol2005;16:625633.

    • Search Google Scholar
    • Export Citation
  • 114

    StiffPJUngerJMFormanSJ. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant2003;9:529539.

    • Search Google Scholar
    • Export Citation
  • 115

    WheelerCEickhoffCEliasA. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin’s disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant1997;3:98106.

    • Search Google Scholar
    • Export Citation
  • 116

    HorningSJChaoNJNegrinRS. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin’s disease: analysis of the Stanford University results and prognostic indices. Blood1997;89:801813.

    • Search Google Scholar
    • Export Citation
  • 117

    JabbourEHosingCAyersG. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer2007;109:24812489.

    • Search Google Scholar
    • Export Citation
  • 118

    MoskowitzAJYahalomJKewalramaniT. Pre-transplant functional imaging predicts outcome following autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Blood2010;116:49344937.

    • Search Google Scholar
    • Export Citation
  • 119

    ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. The International ChlVPP Treatment Group. Ann Oncol1995;6:167172.

    • Search Google Scholar
    • Export Citation
  • 120

    AparicioJSeguraAGarceraS. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol1999;10:593595.

  • 121

    ColwillRCrumpMCoutureF. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol1995;13:396402.

    • Search Google Scholar
    • Export Citation
  • 122

    JostingARudolphCReiserM. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol2002;13:16281635.

    • Search Google Scholar
    • Export Citation
  • 123

    MontotoSCamosMLopez-GuillermoA. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Cancer2000;88:21422148.

    • Search Google Scholar
    • Export Citation
  • 124

    PhillipsJKSpearingRLDaviesJM. VIM-D salvage chemotherapy in Hodgkin’s disease. Cancer Chemother Pharmacol1990;27:161163.

  • 125

    FermeCBastionYLepageE. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol1995;6:543549.

    • Search Google Scholar
    • Export Citation
  • 126

    BartlettNLNiedzwieckiDJohnsonJL. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol2007;18:10711079.

    • Search Google Scholar
    • Export Citation
  • 127

    SantoroAMagagnoliMSpinaM. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica2007;92:3541.

    • Search Google Scholar
    • Export Citation
  • 128

    GopalAKPressOWShustovAR. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multicenter phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma2010;51:15231529.

    • Search Google Scholar
    • Export Citation
  • 129

    SirohiBCunninghamDPowlesR. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol2008;19:13121319.

    • Search Google Scholar
    • Export Citation
  • 130

    GopalAKMetcalfeTLGooleyTA. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience. Cancer2008;113:13441350.

    • Search Google Scholar
    • Export Citation
  • 131

    MoskowitzCHKewalramaniTNimerSD. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol2004;124:645652.

    • Search Google Scholar
    • Export Citation
  • 132

    SweetenhamJWTaghipourGMilliganD. High-dose therapy and autologous stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant1997;20:745752.

    • Search Google Scholar
    • Export Citation
  • 133

    BiermanPJAndersonJRFreemanMB. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin’s disease patients following first relapse after chemotherapy. Ann Oncol1996;7:151156.

    • Search Google Scholar
    • Export Citation
  • 134

    JostingANogovaLFranklinJ. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol2005;23:15221529.

    • Search Google Scholar
    • Export Citation
  • 135

    Roach MIIIBrophyNCoxR. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease. J Clin Oncol1990;8:623629.

    • Search Google Scholar
    • Export Citation
  • 136

    AlvarezISuredaACaballeroMD. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant2006;12:172183.

    • Search Google Scholar
    • Export Citation
  • 137

    SuredaARobinsonSCanalsC. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol2008;26:455462.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 222 224 14
PDF Downloads 33 33 4
EPUB Downloads 0 0 0